Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

The Lancet Neurology

Volumn 16, Issue 7, 2017, Pages 505-512

  Abe, Koji ^a,a   Aoki, Masashi ^a   Tsuji, Shoji ^a   Itoyama, Yasuto ^a   Sobue, Gen ^a,a   Togo, Masanori ^a   Hamada, Chikuma ^a   Tanaka, Masahiko ^a   Akimoto, Makoto ^a   Nakamura, Kazue ^a   Takahashi, Fumihiro ^a   Kondo, Kazuoki ^a   Yoshino, Hiide ^a   Sasaki, Hidenao ^a   Yabe, Ichiro ^a   Doi, Shizuki ^a   Warita, Hitoshi ^a   Imai, Takashi ^a   Ito, Hiroaki ^a   Fukuchi, Mitsumasa ^a   Osumi, Etsuko ^a   Wada, Manabu ^a   Nakano, Imaharu ^a   Morita, Mitsuya ^a   Ogata, Katsuhisa ^a   Maruki, Yuichi ^a   Ito, Kimiko ^a   Kano, Osamu ^a   Yamazaki, Mineo ^a   Takahashi, Yuji ^a   Ishiura, Hiroyuki ^a   Ogino, Mieko ^a   Koike, Ryoko ^a   Ishida, Chiho ^a   Uchiyama, Tsuyoshi ^a   Mizoguchi, Kouichi ^a   Obi, Tomokazu ^a   Watanabe, Hirohisa ^a   Atsuta, Naoki ^a   Aiba, Ikuko ^a   Taniguchi, Akira ^a   Sawada, Hideyuki ^a   Hazama, Takanori ^a   Fujimura, Harutoshi ^a   Kusaka, Hirofumi ^a   Kunieda, Takenobu ^a   Kikuchi, Hitoshi ^a   Matsuo, Hidenori ^a   Ueyama, Hidetsugu ^a   Uekawa, Kazutoshi ^a   Ueda, Masaki ^a   Murakami, Aiko ^a   Sumii, Rie ^a   Kudou, Takuya ^a   Morimoto, Kazunori ^a   Yoneoka, Takatomo ^a   Hirai, Manabu ^a   Sasaki, Kouichi ^a   Terai, Hidetomo ^a   Natori, Tomoko ^a   Matsui, Hiroshi ^a   Kotani, Kuniko ^a   Yoshida, Kaori ^a   Iwasaki, Tomohisa ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATINE KINASE; NORPHENAZONE; PLACEBO; PYROPHOSPHATE; RILUZOLE; PHENAZONE; PHENYLMETHYLPYRAZOLONE; SCAVENGER;

ABDOMINAL DISCOMFORT; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASPIRATION PNEUMONIA; BACKACHE; BILIRUBIN BLOOD LEVEL; CHONDROCALCINOSIS; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; CONTUSION; CREATINE KINASE BLOOD LEVEL; DETERIORATION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ECZEMA; FEMALE; FORCED VITAL CAPACITY; HEADACHE; HUMAN; INSOMNIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SIDE EFFECT; SPEECH DISORDER; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIPYRINE; DOUBLE-BLIND METHOD; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85019648824     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30115-1     Document Type: Article

References (28)

1. Rosen, DR, Siddique, T, Patterson, D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993), 59–62.
2. DeJesus-Hernandez, M, Mackenzie, IR, Boeve, BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron 72 (2011), 245–256.
3. Renton, AE, Majounie, E, Waite, A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72 (2011), 257–268.
4. D'Amico, E, Factor-Litvak, P, Santella, RM, Mitsumoto, H, Clinical perspective of oxidative stress in sporadic ALS. Free Radic Biol Med 65 (2013), 509–527.
5. Garbuzova-Davis, S, Rodrigues, MC, Hernandez-Ontiveros, DG, et al. Amyotrophic lateral sclerosis: A neurovascular disease. Brain Res 1398 (2011), 113–125.
6. Mitsumoto, H, Santella, RM, Liu, X, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 9 (2008), 177–183.
7. Simpson, EP, Henry, YK, Henkel, JS, Smith, RG, Appel, SH, Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62 (2004), 1758–1765.
8. Sohmiya, M, Tanaka, M, Suzuki, Y, Tanino, Y, Okamoto, K, Yamamoto, Y, An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 228 (2005), 49–53.
9. Murata, T, Ohtsuka, C, Terayama, Y, Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci 267 (2008), 66–69.
10. Beal, MF, Ferrante, RJ, Browne, SE, Matthews, RT, Kowall, NW, Brown, RH Jr, Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42 (1997), 644–654.
11. Watanabe, T, Yuki, S, Egawa, M, Nishi, H, Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 268 (1994), 1597–1604.
12. Kawai, H, Nakai, H, Suga, M, Yuki, S, Watanabe, T, Saito, KI, Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 281 (1997), 921–927.
13. Ito, H, Wate, R, Zhang, J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213 (2008), 448–455.
14. The Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15 (2003), 222–229.
15. Cedarbaum, JM, Stambler, N, Malta, E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169 (1999), 13–21.
16. Ohashi, Y, Tashiro, K, Itoyama, Y, et al. Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS-R) Japanese version. No To Shinkei 53 (2001), 346–355 [article in Japanese].
17. Yoshino, H, Kimura, A, Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 7 (2006), 241–245.
18. Abe, K, Itoyama, Y, Sobue, G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 15 (2014), 610–617.
19. Brooks, BR, Miller, RG, Swash, M, Munsat, TL, the World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (2000), 293–299.
20. Bensimon, G, Lacomblez, L, Meininger, V, the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330 (1994), 585–591.
21. Norris, FH Jr, Calanchini, PR, Fallat, RJ, Panchari, S, Jewett, B, The administration of guanidine in amyotrophic lateral sclerosis. Neurology 24 (1974), 721–728.
22. Oda, E, Ohashi, Y, Tashiro, K, Mizuno, Y, Kowa, H, Yanagisawa, N, Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. No To Shinkei 48 (1996), 999–1007 [article in Japanese].
23. Jenkinson, C, Fitzpatrick, R, Brennan, C, Swash, M, Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ-40. Amyotroph Lateral Scler Other Motor Neuron Disord 1 (1999), 33–40.
24. Yamaguchi, T, Ohbu, S, Saito, M, et al. Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis—assessment questionnaire 40 (ALSAQ-40). No To Shinkei 56 (2004), 483–494 [article in Japanese].
25. National Research Council. The prevention and treatment of missing data in clinical trials, 2010, National Academies Press, Washington, DC.
26. Committee for Medicinal Products for Human Use. Guideline on missing data in confirmatory clinical trials, 2010, European Medicines Agency, London.
27. Paolo Messina, Ettore Beghi. Modeling drop-outs in amyotrophic lateral sclerosis. Contemp Clin Trials 33: 218–22.
28. Castrillo-Viguera, C, Grasso, DL, Simpson, E, Shefner, J, Cudkowicz, ME, Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler 11 (2010), 178–180.